EUR 3.82
(-0.65%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -35.46 Million EUR | -10.72% |
2022 | -32.02 Million EUR | -12.25% |
2021 | -28.53 Million EUR | -83.94% |
2020 | -15.51 Million EUR | -44.0% |
2019 | -10.77 Million EUR | -28.16% |
2018 | -8.4 Million EUR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -9.37 Million EUR | -12.38% |
2024 Q2 | -9.37 Million EUR | 0.0% |
2023 Q1 | -9.39 Million EUR | 48.15% |
2023 FY | -35.99 Million EUR | -12.39% |
2023 Q4 | -8.34 Million EUR | 0.22% |
2023 Q3 | -8.35 Million EUR | 57.58% |
2023 Q2 | -19.7 Million EUR | -109.88% |
2022 Q1 | -7.55 Million EUR | 19.26% |
2022 Q3 | -8.46 Million EUR | 47.33% |
2022 Q4 | -18.1 Million EUR | -114.0% |
2022 Q2 | -16.06 Million EUR | -112.75% |
2022 FY | -32.02 Million EUR | -12.25% |
2021 Q1 | -4.91 Million EUR | -11.22% |
2021 FY | -28.53 Million EUR | -83.94% |
2021 Q4 | -9.35 Million EUR | 0.0% |
2021 Q3 | -9.35 Million EUR | -90.41% |
2021 Q2 | -4.91 Million EUR | 0.0% |
2020 Q2 | -3.34 Million EUR | 0.0% |
2020 Q3 | -4.41 Million EUR | -32.23% |
2020 Q1 | -3.34 Million EUR | 0.0% |
2020 FY | -15.51 Million EUR | -44.0% |
2020 Q4 | -4.41 Million EUR | 0.0% |
2019 FY | -10.77 Million EUR | -28.16% |
2018 FY | -8.4 Million EUR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Nicox S.A. | -17.5 Million EUR | -102.611% |
European Medical Solutions | -135 Thousand EUR | -26168.889% |
FERMENTALG | -11.8 Million EUR | -200.33% |
argenx SE | -417.15 Million EUR | 91.499% |
BioSenic S.A. | -7.04 Million EUR | -403.736% |
Celyad Oncology SA | -8.45 Million EUR | -319.333% |
Hyloris Pharmaceuticals SA | -15.99 Million EUR | -121.741% |
Oxurion NV | -12.11 Million EUR | -192.841% |
PHAXIAM Therapeutics S.A. | -23.66 Million EUR | -49.886% |
Financière de Tubize SA | -2.14 Million EUR | -1554.078% |
UCB SA | 604 Million EUR | 105.871% |